Prevalence of POU4F3 and SLC17A8 Mutations

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by University Hospital, Montpellier.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT01802190
First received: July 24, 2012
Last updated: February 27, 2013
Last verified: July 2012
  Purpose

DFNA are characterized as progressive bilateral deafness. To date, 21 genes and 57 loci are involved in these dominant deafness, with an unknown prevalence.A 22nd gene responsible of the disease has been found. This SLC17A8 gene encodes for the VGLUT3 protein which is specifically expressed in sensorial cells of the audition. VGlut3-/- mice present a deep deafness due to a deficiency of neurotransmitter release, although sensorial cells and neurons are intact. This kind of deafness is an ideal candidate for a genetic therapy because of the cells integrity.Mutations of SLC17A8 gene have been found in 2 american families that suffer from progressive deafness.The study aims to look for european families from the Mediterranean basin, which carry SLC17A8 gene mutations, and may benefit in a medium-term from genetic therapy. The study will allow to identify the prevalence of the SLC17A8 gene mutations in patients suffering from deafness. This phenotype also corresponds to DFNA15 deafness caused by POU4F3 : mutations of this gene will be screened as well.


Condition Intervention
Genetic Deafness
Genetic: SLC17A8 et POU4F3 mutations genes analysis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.

Resource links provided by NLM:


Further study details as provided by University Hospital, Montpellier:

Primary Outcome Measures:
  • SLC17A8 et POU4F3 mutations genes analysis [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
    The mutations will be screened by direct sequencing


Secondary Outcome Measures:
  • Phenotypic characterization of the carrier patients [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
    The phenotypic characterization will be assessed by usual tests for genetic deafness (audiometry, electro-physiological explorations)


Estimated Enrollment: 150
Study Start Date: March 2011
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Deafness patients Genetic: SLC17A8 et POU4F3 mutations genes analysis
SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Deafness patients

Criteria

Inclusion Criteria:

  • Age > 18 years
  • Patients with a

    1. suggestive neurosensory Deafness: The characteristics of the deafness will be determined from the data of the questionnaire, of the interrogation, the examination and results of the tonal audiometry.

      *Neurosensory deafness: Audiometrics measurement(difference between the tonal audiometric average loss for the frequencies 0,5, 1, 2 and 4 kHz in air conduction and in osseous conduction) < 15 dB for each of both ears.

      • Bilateral symetric: difference between the audiometric thresholds of both ears < or = 15 dB for at least two frequencies.
      • Light to severe: The degree of deafness is defined according to the following classification (moderate hearing loss calculated on the frequencies 500 Hz, 1, 2 and 4 kHz): light hearing deficiency from 20 to 40 dB, moderate hearing deficiency of 40 to 70 dB, severe hearing deficiency of 70 in 90 dB and deep hearing deficiency beyond 90 dB.
      • Whose thresholds frequency by frequency in tonal audiometry (air conduction) are superior to the thresholds of the 90th percentile of the standard ISO 7029.
      • Without environmental exposition factors.
    2. Dominant autosomal transmission diagnosed from one of the following elements:

      • Deafness at a father and his son
      • Deafness at a father and his daughter outside a suggestive context of a dominant form X-related. (deep deafness at the father and light to moderate deafness in daughter)
      • Deafness at a mother and her daughter
      • Deafness at a mother and her son outside a suggestive context of a dominant X-related(light to moderate deafness at the mother, and deep deafness at the son)
      • Deafness at a patient whose a dead parent had a sure or likely deafness according to the criteria of diagnosis mentioned previously
    3. given the consent to participate at this clinical study

Exclusion Criteria:

  • Suggestive symptom of a polymalformative syndrom
  • familial Consanguinity
  • Age < 18 years
  • Deafness of transmission or mixed
  • Deafness of asymmetric or fluctuating perception
  • Prelingual deep Deafness
  • Pathology of the ear (otospongiose, disease of Ménière, neurinome of the acoustics)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01802190

Contacts
Contact: Michel Mondain, PU-PH m-mondain@chu-montpellier.fr

Locations
France
Mondain Michel Recruiting
Montpellier, France, 34090
Contact: Michel Mondain, PU-PH       m-mondain@chu-montpellier.fr   
Sponsors and Collaborators
University Hospital, Montpellier
  More Information

No publications provided

Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT01802190     History of Changes
Other Study ID Numbers: 8640, 2010-A00561-38
Study First Received: July 24, 2012
Last Updated: February 27, 2013
Health Authority: France: Committee for the Protection of Personnes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Montpellier:
Genetic deafness
SLC17A8 et POU4F3 genes

Additional relevant MeSH terms:
Deafness
Hearing Loss
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 21, 2014